Huoyu Pharmaceuticals (688553.SH): The first subject in the phase I clinical trial of injection HY05350I was administered.
Intelligence Finance APP News, Huayu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary Sichuan Huayu Haiyue Medical Technology Co., Ltd. (referred to as "Huayu Haiyue") independently developed a class 1 innovative biological drug injection HY05350 (research and development project code "HY-0005") is currently undergoing Phase I clinical trials for the treatment of advanced solid tumors. Recently, the first subject successfully completed drug administration.
Latest